NexGel (NXGL) names former CFO Adam Drapczuk interim finance chief

Rhea-AI Filing Summary

NexGel, Inc. reported a leadership change in its finance organization. Effective January 1, 2026, the company appointed Adam E. Drapczuk III as Interim Chief Financial Officer and designated him as principal financial officer and principal accounting officer. He replaces Joseph F. McGuire, whose employment with the company ended on December 31, 2025.

Drapczuk, age 50, previously served as NexGel’s Chief Financial Officer from June 1, 2021 through December 31, 2024 and then as a financial consultant during 2025. He brings prior senior finance experience at several pharmaceutical companies and holds an active CPA license in Pennsylvania. In his new role, he will receive annual cash compensation of $200,000, and the company states he is currently owed approximately $93,000 for prior consulting work. The board also intends to grant him equity under NexGel’s 2019 Long-Term Incentive Plan, with terms to be announced later. The company notes there are no special arrangements, family relationships, or related-party transactions tied to his appointment, and it plans to file an amendment once details of McGuire’s separation are finalized.

Insights

Corporate governance and executive transitions analyst

NexGel names a familiar former CFO as interim finance head, limiting disruption from an executive departure.

NexGel appointed Adam E. Drapczuk III as Interim CFO, principal financial officer, and principal accounting officer effective January 1, 2026, following the termination of Joseph F. McGuire on December 31, 2025. Because Drapczuk previously served as CFO from June 1, 2021 to December 31, 2024 and consulted for the company in 2025, the move maintains continuity in financial leadership rather than introducing a completely new executive.

The filing discloses clear economic terms: annual cash compensation of $200,000 and approximately $93,000 owed for prior consulting services, with a planned equity grant under the 2019 Long-Term Incentive Plan to be detailed later. NexGel also states there are no special arrangements, family ties, or related-party transactions linked to Drapczuk’s appointment, which addresses common governance concerns. The company plans to file an amendment once McGuire’s separation terms are finalized, so later disclosures may clarify any additional financial or contractual implications of this leadership change.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001468929 0001468929 2025-12-31 2025-12-31 0001468929 NXGL:CommonStockParValue0.001Member 2025-12-31 2025-12-31 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2025-12-31 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 31, 2025

NEXGEL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41173		26-4042544
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2150 Cabot Boulevard West, Suite B Langhorne, Pennsylvania		19047
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (215) 702-8550

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		NXGL		The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock		NXGLW		The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of January 1, 2026, NexGel, Inc., a Delaware corporation (the “Company”), appointed Adam E. Drapczuk III as its Interim Chief Financial Officer and designated him as principal financial officer and principal accounting officer of the Company. Mr. Drapczuk replaced Joseph F. McGuire, whose employment with the Company terminated effective as of December 31, 2025.

Mr. Drapczuk, 50, previously served as the Company’s Chief Financial Officer from June 1, 2021 until December 31, 2024 and has continued to serve as a financial consultant to the Company from January 1, 2025 until December 31, 2025. Prior to his roles with the Company, Mr. Drapczuk served as the Financial Controller for R-Pharm US, a private fully integrated specialty pharmaceutical company focused on commercial opportunities to treat cancer and chronic immune diseases from September 2016 to April 2020 and has remained in a consulting role with the company since then. He also served as Vice President of Finance, CFO, for Inpellis, Inc.; Controller and Director of Finance for Tris Pharma; and Director of Finance for West-Ward Pharmaceuticals Corp. Mr. Drapczuk began his career in accounting and finance at KPMG LLP, servicing the firm’s assurance clients. He received his B.S. in accounting at Susquehanna University in Selinsgrove, PA. Mr. Drapczuk holds an active CPA license in the Commonwealth of Pennsylvania.

In connection with his appointment, Mr. Drapczuk will receive annual cash compensation of $200,000. Mr. Drapczuk is currently owed approximately $93,000 by the Company in connection with his role as a financial consultant to the Company. The Board of Directors of the Company also intends to provide Mr. Drapczuk an equity grant under the under the Company’s 2019 Long-Term Incentive Plan, as amended, the terms of which will be announced when determined.

Other than the foregoing, there are no arrangements or understandings between Mr. Drapczuk and any other persons pursuant to which he was selected to serve as the Company’s Interim Chief Financial Officer. There are no family relationships between Mr. Drapczuk and any of the Company’s directors or executive officers. There are no transactions between Mr. Drapczuk and the Company that would be required to be reported under Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

The details of Mr. McGuire’s separation from the Company are being finalized and such details will be filed in a Form 8-K/A once available.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2026
	NEXGEL, INC.
	By:	/s/ Adam Levy
		Adam Levy
		Chief Executive Officer

FAQ

Who did NexGel (NXGL) appoint as Interim Chief Financial Officer?

NexGel appointed Adam E. Drapczuk III as its Interim Chief Financial Officer, and also designated him as the company’s principal financial officer and principal accounting officer, effective January 1, 2026.

Whom is Adam Drapczuk replacing as NexGel (NXGL) CFO and when did that change occur?

Adam Drapczuk replaced Joseph F. McGuire, whose employment with NexGel terminated effective December 31, 2025.

What is the compensation package for NexGel (NXGL) Interim CFO Adam Drapczuk?

In connection with his appointment, Adam Drapczuk will receive annual cash compensation of $200,000. The company also states he is currently owed approximately $93,000 for his prior role as a financial consultant, and the board intends to grant him equity under NexGel’s 2019 Long-Term Incentive Plan, with terms to be announced later.

What prior experience does NexGel (NXGL) Interim CFO Adam Drapczuk have?

Adam Drapczuk previously served as NexGel’s Chief Financial Officer from June 1, 2021 to December 31, 2024 and as a financial consultant during 2025. Before joining NexGel, he held senior finance roles at R-Pharm US, Inpellis, Inc., Tris Pharma, and West-Ward Pharmaceuticals Corp., and began his career at KPMG LLP. He holds an active CPA license in Pennsylvania.

Are there any related-party or family relationships disclosed for NexGel (NXGL) Interim CFO Adam Drapczuk?

The company states there are no arrangements or understandings with other persons regarding his selection, no family relationships between Adam Drapczuk and any NexGel directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.

Will NexGel (NXGL) provide more information about former CFO Joseph McGuire’s separation?

NexGel notes that the details of Joseph F. McGuire’s separation are being finalized and that those details will be filed in an amendment once available.